Counterfeit and Substituted Research Peptides: What Actually Gets Faked
Substitution, dilution, wrong-form supply and underfilled vials — the four ways research peptides are misrepresented, why each is hard to detect, and which analytical test catches which.
"Counterfeit" suggests an elaborate forgery. In the research peptide market the reality is more mundane and harder to detect: material that is genuinely a peptide, genuinely a white powder, and genuinely not what was ordered.
There are four distinct failure modes, and they are caught by different tests.
1. Substitution: a different compound entirely
The vial contains a peptide. It is not the peptide on the label.
The economics drive this wherever price differences are large within a class of structurally similar compounds. Incretin analogues are the clearest case: semaglutide, tirzepatide and retatrutide are related in structure, similar in appearance, similar in chromatographic behaviour, and separated by substantial cost differences.
Why it is hard to detect. All lyophilised peptides look identical. A substituted compound dissolves normally, produces a clean chromatogram, and may well produce an effect in an assay — just not the effect being attributed to it. A purity figure is entirely silent on the question, because it establishes that the vial contains 99% of one thing without establishing what.
What catches it. Mass spectrometry. The masses in these families differ by hundreds of daltons, and observed-versus-theoretical mass resolves the question immediately. See what mass spectrometry establishes that HPLC cannot.
2. Wrong form: the same name, a different molecule
Less deliberate-looking than substitution and more common, because the market's naming conventions permit it.
"TB-500" is used for both full-length thymosin β4 (43 residues, ~4,963 Da) and the Ac-LKKTETQ fragment (7 residues, ~889 Da). The fragment is a fraction of the synthesis cost. Both are sold under the same name, frequently at similar prices.
"CJC-1295" is used for both the DAC form (~3,647 Da) and the non-DAC form (~3,368 Da). These behave differently in any design where duration of receptor occupancy matters, and a research result obtained with one does not transfer to the other.
Why it is hard to detect. The supplier may not be lying by their own lights — the name genuinely is used both ways. The buyer receives the compound they ordered by name and a different molecule than they intended.
What catches it. Mass spectrometry again, and the difference is not subtle. Also: a certificate that states the sequence rather than only the trade name removes the ambiguity at the point of sale.
3. Dilution: real peptide, cut with something
The vial contains the correct peptide mixed with an inert filler — mannitol, lactose, glycine, or simply more salt.
Why it is hard to detect. This is the one that survives a superficial reading of a certificate best. Common fillers do not absorb UV at peptide detection wavelengths, so they are invisible on the chromatogram. Material that is 50% mannitol by mass can return a 99% HPLC purity figure, entirely correctly, because purity describes the peptide-related fraction only.
What catches it. Net peptide content by amino acid analysis, which measures how much peptide is actually present rather than how good the peptide fraction is. This is precisely the distinction covered in net peptide content versus purity — and the reason that article matters beyond concentration arithmetic.
A partial check available without commissioning analysis: dissolve a known mass and observe. Excipient-heavy material often behaves differently — dissolving faster, producing a different cake appearance, or leaving a residue.
4. Underfilling: the right material, less of it
The vial is labelled 10 mg and contains 7 mg. Nothing about the contents is wrong.
Why it is hard to detect. This is the hardest of the four, because both purity and identity testing analyse a sample. Neither weighs the vial. A vial containing 7 mg of 99% pure, correctly identified peptide returns a perfect certificate.
What catches it. Gravimetric verification — weighing the vial before and after removing the contents, which requires an analytical balance and a tare-weight reference. Or quantitative analysis against a known standard, which measures how much peptide is present rather than how good it is.
For most buyers this is impractical, which is why it persists. The realistic mitigation is buying from a supplier where the fill weight is a documented process rather than an assertion.
What documentation covers
| Failure mode | Purity (HPLC) | Identity (MS) | Net peptide content | Gravimetric |
|---|---|---|---|---|
| Substitution | ✗ | ✓ | ✗ | ✗ |
| Wrong form | ✗ | ✓ | ✗ | ✗ |
| Dilution | ✗ | ✗ | ✓ | partial |
| Underfilling | ✗ | ✗ | ✗ | ✓ |
The striking column is the first one. A purity percentage — the number most buyers read and most vendors lead with — catches none of the four.
That is not an argument against purity testing, which addresses a real and different question about synthesis quality. It is an argument against treating purity as the summary statistic for whether material is what it claims to be.
The Australian context
Two things are specific to buying here, and they are frequently conflated.
Domestic dispatch removes transit risk, not analytical risk. A parcel that does not cross a border does not sit in customs, and does not spend weeks in an uncontrolled container. That is a genuine benefit for temperature-sensitive material. It says nothing whatever about what is in the vial — the material was still synthesised somewhere, and a domestic warehouse is a logistics fact rather than a quality control.
"Australian" is a claim that needs unpacking. Australian-owned, Australian dispatch, Australian synthesis and Australian testing are four different claims. Very little research peptide synthesis happens in Australia. Analytical verification is frequently offshore. A supplier who blurs these together — implying domestic testing because they mention domestic dispatch — is telling you something about how precisely they use language generally.
We dispatch from Australia. Independent verification is performed offshore. We keep those separate because they are separate.
What to do
Read the identity result, not the purity figure. Theoretical and observed mass, stated as two numbers.
Insist the certificate carries the batch number on your vial. Without it, nothing on the document is evidence about your material.
Ask for the sequence, not just the name — particularly for TB-500 and CJC-1295, where the name is genuinely ambiguous.
Consider net peptide content where quantity matters, and commission it if the work justifies the cost.
Treat a purity figure as necessary and insufficient. It answers a real question. It is not the question you were most likely to get wrong.
Related: how to spot a fabricated COA and choosing a peptide supplier in Australia.